Treatment durability, satisfaction and quality of life in virologically suppressed HIV-1 people switching to doravirine: Results from the French study DoraVIH.

OBJECTIVES

In Europe, most people with HIV-1(PWH) achieve virologic suppression with effective and well-tolerated antiretroviral therapies (ART). In this context, patient-reported outcomes (PRO) are increasingly important for evaluating ART benefits. This study aimed to describe treatment durability, satisfaction and quality of life (QoL) in virologically suppressed PWH switching to a doravirine-based regimen (PWH-DOR).

METHODS

DoraVIH was a national, multicentre, real-world cohort study with two phases: cross-sectional and prospective follow-up of PWH-DOR at 3 (M3) and 15-18 months (M15-18) post-switch. Durability of the doravirine-based regimen was recorded at both follow-up visits, and on-treatment virologic response at M3. QoL was assessed at baseline (D0) and M15-18 using the SF-36 questionnaire. Pre-switch patient satisfaction with treatment was assessed at D0 using the HIV Treatment Satisfaction Questionnaire (HIVTSQs), and post-switch at M3 and M15-18 using the HIVTSQc.

RESULTS

Among 143 PWH-DOR included (mean age 51.1 ± 10.6 years; 68% men), durability was 94% (131/140) at M3 and 83% (114/138) at M15-18. All participants receiving doravirine at M3 remained virologically suppressed. SF-36 scores showed no significant QoL change between D0 (72.6 ± 17.2) and M15-18 (73.0 ± 19.6). Pre-switch treatment satisfaction averaged 50.2 ± 9.6 (HIVTSQs score). Most PWH-DOR reported better satisfaction (HIVTSQc score >0): 90% at M3 (96/107) and 90% at M15-18 (89/99).

CONCLUSION

Despite the absence of a control group and limited sample size, these real-world data support the effectiveness of switching to a doravirine-based regimen, with high durability and improved patient satisfaction.